Important: This article is educational information only and is not medical advice, a treatment recommendation, or a substitute for care from a qualified prescriber. Epic Journey Recovery is a concierge recovery coaching practice, not a licensed treatment provider or medical practice, and we do not prescribe or manage medication. Every decision about starting, continuing, adjusting, or stopping buprenorphine belongs to you and your prescribing clinician.

How do you actually get off Suboxone, especially the last milligram?

You get off Suboxone the way your prescriber designs it: in small steps, spaced out over months, with the plan for the final milligram decided long before you arrive there. There is no single approved protocol, because no controlled trial has established the best method of tapering at the end of buprenorphine treatment, so every plan has to be individualized with the person who writes your prescription.

Published clinical guidance gives a sense of the shape. A 2025 practical guidance paper in Harm Reduction Journal describes reducing to 8 mg daily or below, then slowing down considerably through a sequence of roughly 4 mg, 2 mg, 1.5 mg, 1 mg, 0.75 mg, and 0.50 mg daily, with the interval between reductions ranging from a week to several months depending on how the person responds. A 2026 review in American Family Physician is more conservative still, suggesting dose reductions of no more than 2 mg per month, adjustments no more often than every one to two months, and at least 12 months of maintenance before a taper is started at all.

The same Harm Reduction Journal paper describes a second route: transitioning to extended release buprenorphine at 300 mg monthly with supplemental buprenorphine and naloxone as needed, then stepping to 100 mg monthly, then discontinuing. That is a described clinical approach, not an FDA protocol, and the authors are explicit that the timeline varies enormously between individuals.

Epic Journey Recovery does not prescribe, does not manage medication, and is not a medical provider. Every dose, every step down, and every decision about whether to taper at all belongs to your prescriber. What follows is context so you can have a better conversation with them.

Why is the last 1 to 2 mg of buprenorphine the hardest part?

The last 1 to 2 mg is hardest because two things stack on top of each other: the arithmetic of the reduction gets brutal, and the psychological meaning of the dose gets heavier. Going from 16 mg to 15 mg is a six percent cut. Going from 1 mg to zero is a one hundred percent cut, and your nervous system reads it that way.

The Harm Reduction Journal guidance names this directly, noting that as the dosage becomes lower, patients may find it more difficult to adjust due to craving and withdrawal symptoms. That is why the published schedules stop using whole milligrams near the bottom and start moving in quarter milligram steps, and why the interval between steps stretches from days to months.

There is a pharmacologic reason the bottom feels different. The SUBLOCADE label reports that the observed plateau for maximal response was reached at buprenorphine plasma concentrations of approximately 2 to 3 ng/mL for illicit opioid use and 4 ng/mL for opioid withdrawal symptoms. Above those concentrations, response is flat. Below them, symptoms have room to come back. Most of a taper is spent on the flat part of that curve, where dropping a dose barely registers. The last stretch is spent going over the edge of it.

Then there is the mechanical problem. Dose forms are not manufactured in fractions of a milligram, so at the bottom of a taper people and prescribers are working with whatever the smallest available strengths allow. Precision gets harder exactly when precision matters most.

None of this means the last milligram is impossible. It means it deserves more time, more support, and more planning than the first fourteen did, and that stalling there is a predictable feature of the pharmacology, not a personal failure.

Does the FDA label say you have to stop buprenorphine at some point?

No. The FDA prescribing information for every form of buprenorphine used in opioid use disorder states plainly that there is no maximum recommended duration of maintenance treatment, and that for some patients treatment may continue indefinitely.

The wording is nearly identical across products. The SUBLOCADE label reads: "There is no maximum recommended duration of maintenance treatment. For some patients, treatment may continue indefinitely." The BRIXADI label carries the same sentence. The SUBOXONE sublingual film label says treatment should continue for as long as patients are benefiting, and the buprenorphine sublingual tablet label repeats the same line.

There is no "four shots and you are done" protocol. If you have seen that claim, it did not come from the label. The label says the opposite: the need for continued treatment should be re-evaluated periodically, which is a clinical conversation, not a countdown.

This matters because the evidence for staying on is strong. A systematic review and meta-analysis in JAMA Psychiatry (Santo et al., 2021) found pooled all-cause mortality of 11.00 deaths per 1000 person-years during opioid agonist treatment compared with 23.97 per 1000 person-years out of it, and found all-cause mortality was six times higher in the four weeks immediately after treatment stopped.

Staying on buprenorphine is a legitimate choice, and for many people it is the best one. Nothing in this article is an argument for stopping. It is an argument for understanding what stopping involves if and when you and your prescriber decide it is right.

What does SUBLOCADE actually change about coming off buprenorphine?

SUBLOCADE changes the shape of the exit rather than the rules of it. Because the medication is released slowly from a subcutaneous depot, blood levels do not drop when you stop taking something, they decline gradually over months, which is the label supported reason the injection can function as a slow taper without anyone hand titrating milligrams.

The numbers come from the label's own pharmacology. The SUBLOCADE prescribing information states that the apparent terminal plasma half-life of buprenorphine following subcutaneous injection ranged between 43 and 60 days as a result of slow release from the depot. It also states that after steady state has been achieved, at four to six months, patients discontinuing SUBLOCADE may have detectable plasma and urine levels of buprenorphine for twelve months or longer, and that the patient should be monitored for several months for signs and symptoms of withdrawal.

A few practical points from the label:

The long tail is not automatically gentle. A 2026 case report in Frontiers in Psychiatry describes a patient who was stable after a last long acting injection and then developed withdrawal symptoms roughly four months later. The authors challenge the assumption that long acting injectable buprenorphine reliably produces a smoother taper and call for extended monitoring and explicit informed consent about delayed withdrawal.

What does BRIXADI add that SUBLOCADE does not?

BRIXADI adds granularity. Where SUBLOCADE offers two monthly strengths, BRIXADI is approved in weekly doses of 8 mg, 16 mg, 24 mg, and 32 mg and monthly doses of 64 mg, 96 mg, and 128 mg, which gives a prescriber more places to stand between full maintenance and nothing.

The BRIXADI label also describes a shorter tail. After steady state, patients discontinuing the weekly formulation may have detectable plasma buprenorphine for approximately one month, and patients discontinuing the monthly formulation for approximately four months. Compare that with SUBLOCADE, where levels can be detectable for twelve months or longer. Neither is better in the abstract. A longer tail means longer passive protection and a longer period during which delayed withdrawal can surface. A shorter tail means a more predictable off ramp and less residual coverage.

Initiation differs too. The label directs that a patient not already on buprenorphine receive a test dose of transmucosal buprenorphine 4 mg when objective signs of mild to moderate withdrawal appear before starting the weekly formulation, while patients already stable on transmucosal buprenorphine can transition directly to either the weekly or monthly product. Like SUBLOCADE, BRIXADI is available only through a restricted REMS program.

And like every other buprenorphine product, the BRIXADI label states there is no maximum recommended duration of maintenance treatment and that treatment may continue indefinitely. It also directs that on discontinuation the patient should be monitored for several months for signs and symptoms of withdrawal.

What neither product offers is a validated stopping protocol. Both labels tell prescribers how to start and how to maintain. Neither tells them how to finish, because the trials that would answer that question have not been done. Anyone presenting an injection schedule as a guaranteed path off buprenorphine is going beyond the evidence.

What does a daily dose do psychologically, and what changes with a monthly injection?

A daily dose keeps a daily decision alive, and that decision carries meaning far beyond the pharmacology. This next part is clinical observation and what people consistently describe, not a proven outcome and not a reason to leave a medication that is working.

Here is the pattern Preston Durnford has seen across more than a decade of running treatment programs and 500 plus interventions. When you take something every single morning to be okay, the ritual quietly teaches a lesson: my baseline is something I administer. For someone whose whole history is with substances that had to be taken to feel right, that daily motion can sit uncomfortably close to the old pattern, even when the medication itself is doing exactly what it is supposed to do.

The second thing a daily dose leaves room for is self adjustment. A hard day arrives, a fight, a bad phone call, a wave of grief, and there is a bottle or a box within reach and a dose that could be taken a little early or a little large. Most people do not do this most of the time. But the option is present every day, and the presence of the option keeps the old decision loop running: something happened, so what do I take.

A monthly injection removes both. There is no morning ritual to interpret and no dose to adjust when emotions spike, so a hard Tuesday has to be handled some other way. People often describe that as the moment recovery started feeling like a life rather than a regimen.

Two honest caveats. First, some people find the loss of control unsettling rather than freeing, and that is a real and valid reaction worth naming with a prescriber before switching. Second, none of this is a reason to move someone off a medication that is stabilizing them. A daily film that is keeping someone alive is doing its job.

What are the real risks of stopping, and what kind of support lowers them?

The central risk is that tolerance falls while the environment does not change, so a return to use after stopping carries a much higher chance of overdose than the same use would have carried before. The JAMA Psychiatry meta-analysis found all-cause mortality six times higher in the four weeks after opioid agonist treatment ended, and roughly double for the remaining time off treatment.

The published guidance is consistent about what reduces that risk: longer maintenance before tapering, slower reductions, keeping naloxone on hand, keeping a supply of buprenorphine available in case of return to use, and staying in regular contact with a clinician rather than disappearing once the last dose is taken. The American Family Physician review is direct that close follow up should continue after a taper is complete, including assessing whether treatment needs to restart. Restarting is not a failure. It is one of the planned outcomes.

Epic Journey Recovery is concierge recovery coaching based in Newport Beach, California, working mainly virtually nationwide and in person across Orange County. We are not a treatment facility, we have no beds, we are not licensed treatment, we do not bill insurance, and we do not prescribe. What we do is the non medical scaffolding around a taper your prescriber runs: structure through the weeks when sleep and mood get unreliable, accountability that is not a monthly appointment, sleep and nutrition support, and the psychological work of separating who you are from what you take every morning.

The team is about twelve people, including coaches, holistic practitioners, functional medicine, a neurologist, a psychiatrist, and licensed therapists, with psychiatry coordinated when appropriate. Engagement is a 90 day core with the full team. Most people stay up to about six months, then taper to roughly one session a week with whichever team member they connected with most.

If you want to think this through with someone, book a free consult.

Questions people ask

How long does it take to taper off Suboxone?

There is no established answer, and anyone quoting a fixed number is guessing. Published guidance suggests at least 12 months of maintenance before starting, then reductions of no more than about 2 mg per month with adjustments every one to two months. Extended release approaches are described as ranging from one month to several months. Your prescriber sets the timeline.

Can SUBLOCADE get you off Suboxone completely?

The label does not say that, and no controlled trial has established it. What the label does support is that buprenorphine levels decline slowly for months after the last injection, with an apparent terminal half-life of 43 to 60 days, which can function as a gradual taper. It also directs monitoring for withdrawal for several months afterward.

Is it dangerous to stop Suboxone?

Stopping lowers your opioid tolerance, which raises overdose risk substantially if you return to use. Research found all-cause mortality six times higher in the four weeks after opioid agonist treatment ended. That is not a reason never to stop. It is a reason to stop slowly, with a prescriber, with naloxone available and follow-up in place.

Do I have to come off buprenorphine eventually?

No. The FDA prescribing information for buprenorphine products states there is no maximum recommended duration of maintenance treatment and that for some patients treatment may continue indefinitely. Staying on it is a legitimate and often the best clinical choice. The label asks only that the need for continued treatment be re-evaluated periodically with your prescriber.

Does Epic Journey Recovery prescribe or manage Suboxone?

No. Epic Journey Recovery is concierge recovery coaching, not a medical provider and not licensed treatment, and we do not prescribe or manage medication. Every medication decision belongs to your prescriber. We provide the non-medical support around a taper they run: structure, accountability, sleep and nutrition support, and the identity work underneath it.

Sources